MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2023-24)
- Udyam number
- UDYAM-HP-11-0003297
Medipol Pharmaceutical India Private Limited - pharma in Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹49.73 Cr
▲ 10% YoY
Net profit · FY 2025
₹1.52 Cr
Net margin 3.1%
EBITDA · FY 2025
₹5.16 Cr
EBITDA margin 10.4%
Authorised capital
₹11 Cr
Registered with MCA
Paid-up capital
₹6.69 Cr
Issued & subscribed
Open charges
₹20.9 Cr
Satisfied ₹8.27 Cr
Company age
34 yrs
Est. 1992
Employees · EPFO
64
Provident fund records
About Medipol Pharmaceutical India Private Limited
Data last updated:
Medipol Pharmaceutical India Private Limited is a private limited company based in Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 May 1992 and has been in existence for over 34 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24231DL1992PTC363074. Its GSTIN is 07AABCM8501G1ZP (Delhi). The company holds 13 GST registrations, of which 6 are active.
The company has an authorised share capital of ₹11 Cr and a paid-up capital of ₹6.69 Cr. It was formerly known as Kansal Associates Pvt Ltd. It is led by directors including Yogesh Gupta and Umesh Kumar Gupta.
Its last annual general meeting (AGM) was held on 30 December 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 1/2344 Subhash Marg Ram Nagar Shahdara, Delhi, India – 110032.
As per the financials filed for FY 2025, the company reported a revenue of ₹49.73 Cr, a growth of 10% compared to the previous year. For the same year it recorded a net profit of ₹1.52 Cr (net margin 3.1%) and EBITDA of ₹5.16 Cr (EBITDA margin 10.4%). Revenue has declined at a compounded annual rate (CAGR) of 11% over three years and 10% over five years.
The company has about 64 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Medipol. As per MCA filings, the company has open charges of ₹20.9 Cr and satisfied charges of ₹8.27 Cr on record. Court records list 156 cases involving the company, including 90 filed by the company and 66 filed against it; 29 cases are pending. The company has 5 deals on record (3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹1.58 Cr; the latest was in July 2019. Its 4 peer companies in the Healthcare industry (Formulations, Medical Consumables), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 2 smaller; the largest is Spica Laboratories Private Limited with revenue of ₹50.21 Cr. The company has 2 MSME Form 1 returns on record for the period ending Sep 2019, listing 2 overdue payments to 1 micro and small supplier.
Medipol Pharmaceutical India Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-HP-11-0003297). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medipol.in.
Company details
CIN U24231DL1992PTC363074
Registration Number 363074
Incorporation Date 01 May 1992
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 December 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-HP-11-0003297
CIN history
Medipol Pharmaceutical India has one previous CIN (Corporate Identification Number): U24231HR1992PTC031641. The current CIN is U24231DL1992PTC363074, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231DL1992PTC363074 | Current |
| U24231HR1992PTC031641 | Previous |
Recognitions & Rankings of Medipol Pharmaceutical India
Contact details
Medipol Pharmaceutical India Private Limited's registered office is in Delhi, Delhi. Its website is medipol.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address1/2344 Subhash Marg Ram Nagar Shahdara, Delhi, India – 110032
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Medipol Pharmaceutical India Private Limited, buy the company report.
Comprehensive company report
Medipol Pharmaceutical India Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Medipol Pharmaceutical India operates one associated brand: Medipol. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical production, distribution, and export of medications and medical supplies in India. | medipol.in |
Business activity
The main business activity of Medipol Pharmaceutical India is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Medipol Pharmaceutical India Private Limited, buy the company report.
Financials of Medipol Pharmaceutical India Private Limited
FY 2024 filings availableMedipol Pharmaceutical India Private Limited reported revenue of ₹49.73 Cr (up 10% YoY) for FY 2025.
Revenue · FY 2025
₹49.73 Cr ▲ 10%
Net profit · FY 2025
₹1.52 Cr margin 3.1%
EBITDA · FY 2025
₹5.16 Cr margin 10.4%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 10%
3 years · compounded
▼ 11%
5 years · compounded
▼ 10%
EBITDA CAGR growth
1 year
▲ 43%
3 years · compounded
▲ 6%
5 years · compounded
▼ 2%
Revenue rose 10% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 10%. EBITDA rose 43% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹5.16 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.52 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 10.4% | ||||
| Net Profit Margin | 3.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Medipol Pharmaceutical India Private Limited, buy the company report.
Board of directors of Medipol Pharmaceutical India Private Limited
Medipol Pharmaceutical India has 3 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Yogesh Gupta | Director | 11 Oct 1999 | 27 Years 0 Months | Current |
| Umesh Kumar Gupta | Director | 01 Mar 2004 | 22 Years 8 Months | Current |
| Sanjay Agarwal | Director | 07 Dec 2023 | 2 Years 11 Months | Current |
Peer comparison
Medipol Pharmaceutical India Private Limited is compared with the 4 companies closest to it by revenue in the Healthcare industry (Formulations, Medical Consumables), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Spica Laboratories Private Limited | ₹50.21 Cr (FY 2025) | -4.0% | Hyderabad, Telangana, India | |||
| Sotac Healthcare Private Limited | ₹49.75 Cr (FY 2025) | 7.0% | Ahmedabad, Gujarat, India | |||
| Medipol Pharmaceutical India Private Limitedthis company | ₹49.73 Cr (FY 2025) | ₹1.52 Cr | 3.1% | 10.0% | 64 | Delhi, India |
| Akron Formulations India Private Limited | ₹49.28 Cr (FY 2025) | 83.0% | Hyderabad, Telangana, India | |||
| Kivi Labs Limited | ₹49.21 Cr (FY 2025) | 6.0% | Por, Gujarat, India |
To see the full peer comparison of Medipol Pharmaceutical India Private Limited, buy the company report.
Auditor
Medipol Pharmaceutical India Private Limited is audited by Aarti Vohra & Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Aarti Vohra & Associates | FY 2024 | 031377N |
Shareholding
The shareholding of Medipol Pharmaceutical India Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Medipol Pharmaceutical India Private Limited, buy the company report.
Charges & borrowings
Open charges
₹20.9 Cr
Satisfied charges
₹8.27 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 24 Jan 2011 | 10270993 | Hdfc Bank Limited | ₹20.9 Cr | Open | |
| 16 Jan 2008 | 10086345 | State Bank of India | ₹5.8 Cr | Satisfied | |
| 16 Jan 2008 | 10086348 | State Bank of India | ₹73 Lakh | Satisfied | |
| 28 Mar 2005 | 80041535 | Bank of Maharashtra | ₹1.4 Cr | Satisfied | |
| 28 Mar 2005 | 80041536 | Bank of Maharashtra | ₹34 Lakh | Satisfied |
To see the full charge records of Medipol Pharmaceutical India Private Limited, buy the company report.
Total charge records: 5 View all charges
Deals & funding
Medipol Pharmaceutical India Private Limited has 5 deals on record (3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹1.58 Cr; the latest was in July 2019.
Total deals
5
Secondary share transfers
3
Funding rounds
2
Disclosed funding
₹1.58 Cr
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2019 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 4 individuals |
| Jun 2019 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| Aug 2016 | Funding round | ₹1.08 Cr | Investors: 4 individuals |
| Dec 2007 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Dec 2007 | Funding round | ₹50 Lakh | Investors: 4 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Medipol Pharmaceutical India Private Limited has 156 court cases on record: 90 filed by Medipol Pharmaceutical India, 66 filed against it. 29 cases are pending and 127 are disposed.
Total cases
156
Filed by the company
90
Filed against the company
66
Pending
29
Disposed
127
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 90 | 57 | 17 |
| High courts | 57 | 8 | 11 |
| NCLAT | 6 | 0 | 0 |
| Supreme Court | 2 | 0 | 0 |
| NCLT | 1 | 1 | 1 |
Cases on record (5 of 156)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Shimla, Himachal Pradesh | Arbitration matter | Filed against the company by Interlinks Overseas Pvt. Ltd. | Pending |
| District court, Shahdara, Delhi | Interim or miscellaneous application | Filed against the company by Trans India International Ltd | Disposed |
| High Court of Delhi | Court case (CM(M)) | Filed against the company by Trans India International Ltd. | Disposed |
| District court, Jodhpur Metro, Rajasthan | Criminal case | Filed against the company by State of Rajasthan | Pending |
| District court, Ganganagar, Rajasthan | Criminal case | Filed against the company by State | Pending |
To see the full case history of Medipol Pharmaceutical India Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Medipol Pharmaceutical India Private Limited has 2 MSME Form 1 returns on record for the period ending Sep 2019, listing 2 overdue payments to 1 micro and small supplier. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (1 of 1)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Baddi Foils Private Limited |
To see the full MSME payment records of Medipol Pharmaceutical India Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Medipol Pharmaceutical India Private Limited has a workforce of 64 employees on its EPFO records as of Feb 27, 2025, across 1 active EPFO establishment.
Employee count
64
Active EPFO establishments
1
Employee growth
-13.51%
GST
Medipol Pharmaceutical India has 13 GST registrations: 6 active and 7 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
13
Active
6
Cancelled / inactive
7
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AABCM8501G1ZP | Delhi | Active | 01 Jul 2017 |
| 02AABCM8501G2ZY | Himachal Pradesh | Active | 01 Jul 2017 |
| 21AABCM8501G1ZZ | Odisha | Active | 01 Jul 2017 |
| 09AABCM8501G2ZK | Uttar Pradesh | Active | 27 Dec 2021 |
To see the full GST registrations and return filing status of Medipol Pharmaceutical India Private Limited, buy the company report.
Recent activity
Medipol Pharmaceutical India Private Limited has 11 board changes on record since 1999: 3 appointments and 8 cessations. The latest: Umesh Kumar Gupta ceased to be Director on 01 Dec 2025.
Ceased
Umesh Kumar Gupta ceased to be Director.
AGM
Medipol Pharmaceutical India Private Limited last Annual general meeting of members was held on 30 Dec 2024 as per latest MCA records.
Ceased
Yogesh Gupta ceased to be Director.
Filing
Medipol Pharmaceutical India Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.
Appointed
Sanjay Agarwal was appointed as Director.
Ceased
Aditya Gupta ceased to be Additional Director.
Charges
A charge with Hdfc Bank Limited of Rs. 20.90 Cr registered on 24 Jan 2011 with Charge ID 10270993 was modified on 26 Sep 2020.
Ceased
Jagdish Kumar Gupta ceased to be Director.
Ceased
Ram Babu Gupta ceased to be Director.
Charges
A charge registered on 16 Jan 2008 via Charge ID 10086345 with State Bank Of India was fully satisfied on 07 Apr 2011.
Charges
A charge registered on 16 Jan 2008 via Charge ID 10086348 with State Bank Of India was fully satisfied on 07 Apr 2011.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 20.90 Cr with Charge ID 10270993 was registered on 24 Jan 2011.
14 earlier events are in the company report.
Frequently asked questions
Medipol Pharmaceutical India is an active private limited company based in Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 May 1992 (34+ years old) and is registered under CIN U24231DL1992PTC363074.
Medipol Pharmaceutical India has 3 current directors:
- Yogesh Gupta - Director
- Umesh Kumar Gupta - Director
- Sanjay Agarwal - Director
The latest financial statements of Medipol Pharmaceutical India on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 December 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Medipol Pharmaceutical India is 07AABCM8501G1ZP, registered in Delhi. The company has 13 GST registrations in all, of which 6 are active and 7 are cancelled or inactive. Other active GSTINs include 02AABCM8501G2ZY (Himachal Pradesh), 21AABCM8501G1ZZ (Odisha), 09AABCM8501G2ZK (Uttar Pradesh).
The CIN (Corporate Identification Number) of Medipol Pharmaceutical India is U24231DL1992PTC363074. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Medipol Pharmaceutical India has 156 court cases on record: 90 filed by the company and 66 filed against it. 29 are pending. Most are in the district courts.
Medipol Pharmaceutical India was incorporated on 01 May 1992, making it 34+ years old. It is registered with the Registrar of Companies, Delhi.
Medipol Pharmaceutical India has 5 deals on record (3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹1.58 Cr; the latest was in July 2019.
The peers of Medipol Pharmaceutical India by revenue are Spica Laboratories Private Limited, Sotac Healthcare Private Limited, Akron Formulations India Private Limited, Kivi Labs Limited, all in the Healthcare industry (Formulations, Medical Consumables), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Umesh Kumar Gupta ceased to be Director on 01 Dec 2025. Yogesh Gupta ceased to be Director on 04 Oct 2024. Sanjay Agarwal was appointed as Director on 07 Dec 2023. Medipol Pharmaceutical India has 11 board changes on record in total.
Yes, Medipol Pharmaceutical India is registered as a medium enterprise under Udyam registration (number: UDYAM-HP-11-0003297).
Medipol Pharmaceutical India has 2 MSME Form 1 returns on record for the period ending Sep 2019, listing 2 overdue payments to 1 micro and small supplier. The latest return was filed on 31 Oct 2019.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages